- Home
- TBPH
as of 12-04-2025 4:00pm EST
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | GEORGE TOWN, GRAND CAYMAN |
| Market Cap: | 993.7M | IPO Year: | N/A |
| Target Price: | $27.80 | AVG Volume (30 days): | 601.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.58 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.90 - $20.33 | Next Earning Date: | 11-10-2025 |
| Revenue: | $80,327,000 | Revenue Growth: | 27.12% |
| Revenue Growth (this year): | 70.78% | Revenue Growth (next year): | -19.42% |
AI-Powered TBPH Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Theravance Biopharma Inc. (TBPH)
Director
Avg Cost/Share
$20.00
Shares
29,501
Total Value
$590,020.00
Owned After
60,204
Director
Avg Cost/Share
$18.00
Shares
59,000
Total Value
$1,068,250.00
Owned After
60,204
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| BROSHY ERAN | TBPH | Director | Nov 26, 2025 | Sell | $20.00 | 29,501 | $590,020.00 | 60,204 | |
| BROSHY ERAN | TBPH | Director | Nov 11, 2025 | Sell | $18.00 | 59,000 | $1,068,250.00 | 60,204 |
Compare TBPH vs Leading Stocks
See how TBPH stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "TBPH Theravance Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.